Antoni Ribas

Antoni Ribas is a leading translational scientist bridging basic immunology with clinical cancer care. His research has been instrumental in understanding mechanisms of response and resistance to immune checkpoint inhibitors, particularly in melanoma. Ribas has led numerous practice-changing clinical trials and contributed to FDA approvals of multiple immunotherapy agents.

Antoni Ribas是连接基础免疫学与临床癌症护理的领先转化科学家。他的研究在理解免疫检查点抑制剂反应和耐药机制方面发挥了重要作用，特别是在黑色素瘤中。Ribas领导了众多改变实践的临床试验，并为多种免疫治疗药物的FDA批准做出了贡献。